Arsanis, Inc. Appoints David Mantus As Executive Vice President, Regulatory Affairs, Clinical And Technical Operations

BOSTON and VIENNA, Nov. 4, 2015 /PRNewswire/ -- Arsanis, Inc., a development-stage biopharmaceutical company focused on monoclonal antibody therapeutics for severe infectious diseases, today announced that David Mantus, Ph.D., has joined the company as Executive Vice President, Regulatory Affairs, Clinical and Technical Operations. Dr. Mantus will oversee all facets of Arsanis' global regulatory affairs, including filings and interactions with the major regulatory authorities around the world as well as clinical operations, manufacturing and quality. Dr. Mantus will report to Rene Russo, PharmD, BCPS, Arsanis' Chief Development Officer.

Dr. Mantus joins Arsanis from BIND Therapeutics, where he served as Vice President, Regulatory Affairs and Quality Assurance. Prior to BIND, Dr. Mantus was Vice President of Regulatory Affairs at Cubist Pharmaceuticals.

"I am delighted that Dave Mantus has chosen to join Arsanis and become a member of our management team," said Dr. Russo. "Dave is a senior biotechnology leader who brings a strong mix of creativity, global experience, and strategic thinking to Arsanis. We look forward to having him help us realize our vision of translating exciting and novel science into precision therapies that target specific important pathogens."

Prior to his time at Cubist, Dr. Mantus held various senior regulatory roles at Sention Inc, Shire Biologics, and PAREXEL. He has also held positions at the Massachusetts Public Health Laboratory and Procter and Gamble Pharmaceuticals, as well as leading a regulatory affairs consulting practice. Dr. Mantus is a co-author of a book on regulatory affairs, "FDA Regulatory Affairs: A Guide for Prescription Drugs, Medical Devices, and Biologics," that is in its third edition. He has published numerous scientific papers and done presentations around the world. Dr. Mantus received his B.S. in Chemistry at the College of William and Mary, his M.S. and Ph.D. in Chemistry from Cornell University and was a post-doctoral research fellow in Biomedical Engineering at the University of Washington.

About Arsanis

Arsanis, Inc. is a development-stage company creating precision therapeutics for serious bacterial infections not effectively controlled by currently available treatments. The company applies its extensive knowledge of infectious disease biology to design optimal human monoclonal antibody therapeutics that precisely target pathogens directly and/or support host defenses against the infecting bacteria and their toxins. The company is building a broad product pipeline addressing the most important Gram-positive and Gram-negative bacterial pathogens threatening hospitalized and high-risk patients, with its lead therapeutic candidate, ASN100, aimed at the prevention and treatment of serious Staphylococcus aureus infections and expected to enter clinical development in the fall in 2015. Arsanis, Inc. is a U.S. company headquartered in Boston, Massachusetts, with European research and pre-clinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH). For more information, please visit the Arsanis website at

Logo -


To view the original version on PR Newswire, visit:

SOURCE Arsanis, Inc.

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Janssen is tapping little-known and privately held Hemera Biosciences for a new gene therapy aimed at reversing a severe disease.

Harvard scientists showed that a three-gene cocktail, by epigenetic reprogramming, could reverse the aging clock in mice retina nerve cells.

Merck is clearly still buzzing about its two-year Dragonfly Therapeutics pact, as it has snapped up a cancer program.